F03225 – COPD Trial
This clinical research study is testing an investigational medication, to see whether it can help people living with moderate to very severe chronic obstructive pulmonary disease (COPD). The study will compare the investigational medication (tablets) with placebo to understand if the treatment can reduce COPD flare-ups (exacerbations), improve lung function, and support overall quality of life.
Participants will continue their regular COPD treatment and attend scheduled study visits over approximately 24 weeks. The study includes health checks, breathing tests, and monitoring of symptoms with care provided by specialist clinical research staff.
Eligibility requirements
- Age: 40 years and older
- Sex: M & F
- BMI: Between 18 and 44.9
- Medication: Must be on stable COPD maintenance therapy (such as inhalers) before joining; cannot use certain other medications that interfere with study results (the study team will advise)
- Medical History: Must have a diagnosis of COPD for at least 12 months, with a history of recent flare-ups (exacerbations). Cannot take part if you have other major lung conditions (like asthma, pulmonary fibrosis, cystic fibrosis), serious recent heart problems, or active infections. Cannot have an unstable disorder affecting but not limited to: gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, or major physical and/or cognitive impairment.
- Smoking History: Must be a current or former smoker with at least 10 pack-years history (e.g., one pack a day for 10 years), but e-cigarettes or vapes do not count towards the smoking history.
Outpatient Visits
- 9 visits including 2 screening visits over approximately 32 weeks
Payment/Remuneration
- Reimbursement for time and travel may be available (details provided by the study team).
How to apply
To register your interest in this trial, please complete the form below, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.